title: Dual DAT/sigma1 receptor ligands based on 3-(4-(3-(bis(4-fluorophenyl)amino)propyl)piperazin-1-yl)-1-phenylpropan-1-ol.
abstract: Ester analogs of (+/-)3-(4-(3-(bis(4-fluorophenyl)amino)propyl)piperazin-1-yl)-1-phenylpropan-1-ol were synthesized and evaluated for binding at DAT, SERT, NET, and sigma1 receptors, and compared to GBR 12909 and several known sigma1 receptor ligands. Most of these compounds demonstrated high affinity (K(i)=4.3-51 nM) and selectivity for the DAT among the monoamine transporters. S- and R-1-(4-(3-(bis(4-fluorophenyl)amino)propyl)piperazin-1-yl)-3-phenylpropan-2-ol were also prepared wherein modest enantioselectivity was demonstrated at the DAT. However, no enantioselectivity at sigma1 receptors was observed and most of the ester analogs of the more active S-enantiomer showed comparable binding affinities at both DAT and sigma1 receptors with a maximal 16-fold DAT/sigma1 selectivity.
authors.affiliation: Medicinal Chemistry Section, National Institute on Drug Abuse-Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, MD 21224, USA.
authors.forename: Jianjing
authors.initials: J
authors.lastname: Cao
authors.forename: Theresa
authors.initials: T
authors.lastname: Kopajtic
authors.forename: Jonathan L
authors.initials: JL
authors.lastname: Katz
authors.forename: Amy Hauck
authors.initials: AH
authors.lastname: Newman
mesh_terms: D000818:Animals; D002227:Carbazoles / Q000737:chemistry / Q000494:pharmacology; D003042:Cocaine / Q000494:pharmacology; D020650:Combinatorial Chemistry Techniques; D050483:Dopamine Plasma Membrane Transport Proteins / Q000378:metabolism*; D015394:Molecular Structure; D010879:Piperazines / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D011485:Protein Binding; D051381:Rats; D017480:Receptors, sigma / Q000378:metabolism; D013237:Stereoisomerism; D013329:Structure-Activity Relationship
chemical_list: C532461:3-(4-(3-(bis(4-fluorophenyl)amino)propyl)piperazin-1-yl)-1-phenylpropan-1-ol; D002227:Carbazoles; D050483:Dopamine Plasma Membrane Transport Proteins; D010879:Piperazines; D017480:Receptors, sigma; C043425:vanoxerine; C034931:rimcazole; D003042:Cocaine
references.citation: Eur J Pharmacol. 1991 Aug 29;201(2-3):251-2
references.pmid: 1686761
references.citation: Bioorg Med Chem Lett. 2001 Dec 17;11(24):3169-73
references.pmid: 11720867
references.citation: Neurosci Biobehav Rev. 2002 Jun;26(4):499-527
references.pmid: 12204195
references.citation: J Med Chem. 2008 May 8;51(9):2795-806
references.pmid: 18393401
references.citation: J Med Chem. 2003 Jun 19;46(13):2589-98
references.pmid: 12801223
references.citation: J Med Chem. 2002 Sep 12;45(19):4097-109
references.pmid: 12213053
references.citation: Eur J Pharmacol. 1993 Oct 19;243(2):201-5
references.pmid: 8276070
references.citation: J Med Chem. 1999 Oct 21;42(21):4446-55
references.pmid: 10543888
references.citation: Neuropsychopharmacology. 2002 Apr;26(4):444-55
references.pmid: 11927169
references.citation: Neuropharmacology. 2001 Dec;41(7):878-86
references.pmid: 11684152
references.citation: CNS Drug Rev. 2004 Spring;10(1):1-22
references.pmid: 14978511
references.citation: Neuroreport. 2000 Sep 11;11(13):2885-8
references.pmid: 11006959
references.citation: J Med Chem. 2006 Mar 9;49(5):1766-72
references.pmid: 16509591
references.citation: Eur J Pharmacol. 2003 May 9;468(2):109-19
references.pmid: 12742518
references.citation: J Med Chem. 2004 Jun 17;47(13):3388-98
references.pmid: 15189035
references.citation: Med Res Rev. 2002 Sep;22(5):429-64
references.pmid: 12210554
references.citation: Mol Pharmacol. 2008 Mar;73(3):813-23
references.pmid: 17978168